We describe a dual-channel AutoAnalyzer (Technicon) system for the simultaneous measurement of phenytalanine and galactose from blood specimens on filter-paper. Using a single #{188}-in.-diameter (6-mm) specimen, we measure both components fluorometrically at a rateof 70/h. Analytical recoverywiththe method and the linearity ofmeasurements vs sample concentration are excellent through the ranges of interest, 0-200 mg/L for phenylalanine and 0-800 mg/L for galactose. Carryover at the critical values during screening, 40 mg/L for phenylalanine and 100 mg/L for galactose, is essentially zero. The dual-channel system provides the means to incorporate a low-incidence test, i.e., galactosemia (incidence 1/70 000), into an existing program for phenylalanine analysis, for which the higher rates (phenylketonuria, incidence 1/11 500) easily justify the cost of mass screening.
automated PA/GAL system adapted to the AutoAnalyzer II (Technicon Corp., Tarrytown, NY 10591), by which significant savings in laboratory personnel costs make the GAL screening procedure cost effective.
Materials and Methods

Reagents
All reagentsare prepared with de-ionized water filtered through a 0.45-sm pore-size filter; the reagents are also filtered after preparation. Except as noted, reagentsare reagent-grade, from Sigma Chemical Co.,St.Louis, MO 63178. Wash reagent. (MultiTurge' ; Harleco Reagents, Gibbstown, NJ 08027). Mix 50 mL of commercial reagent per liter ofde-ionized water.
Sodium hydroxide stock (2.5 mol/L).
Dissolve 100 g of reagent-grade NaOH in de-ionized water. For working reagent, dilute 14-16 mL of stock to 100 mL, the exact volume of stock being dependent on the precise characteristics of the pump tubing used. Adjust volume until the pH measured after the first mixing coil in the flow diagram ( Figure 1 ) is 5.3 to 5.5. The precise amount required is usuallyreproducible over a given lotofpump tubes.
Copper reagent. Dissolve 16 g of sodium carbonateand 650mg of potassium sodium tartrate in 600 mL of de-ionized water. In a separate flask, dissolve 0.600 g of CuSO4 . 5HO in 250 mL of de-ionized water. Add the copper solution to the tartrate, dilute to 1 L, and filter.
Dipeptide. Dissolve 2.4 g of L-leucyl-L-alanine in 150 mL of de-ionized water. Prepare weekly, store refrigerated when not in use.
Ninhydrin.
Dissolve3.624 g of ninhydrin in 150 mL of water, filter, and store in a brown bottle. Prepare freshly each week, store at room temperature.
Tris buffer (pH 8.6 at 25 #{176}C). To prepare stock buffer, dissolve 12.1 g of Tris in 750 mL of water. Add 122 mL of 0.2 molIL HC1, dilute to 1 L. This reagent is stable for one month, when stored refrigerated.
For reagent Tris buffer, dissolve 7.26 g of Tris in 100 mL ofwater.Preparefreshly each week, storeatroom temperature.
NAD
reagent. Dissolve 320 mg of NAD in 100 mL of stock Tris buffer; thisisstable for 48 h, refrigerated.
Galactose dehydrogenase.
Pipet 0.450 mL of galactose dehydrogenase (EC 1. Table 1 lists a schedule of reagent preparation. To start the analyzer, pump water for 10 mm, air for 5 mm, and reagents for20 mm. Reagent baselines are set by running the dilute TCA solution; the detector is set at 0.080and 0.100 of full-scale for PA and GAL, respectively. Set the sensitivity on both channels by adjusting the steadystate response on the 200/800 PA/GAL standard to 0.95 and 0.90 of full-scale, respectively. Standards are run in a "double-staircase" ascending order, followed by samples and controls; a control is analyzed every 20th cup. Standards are repeated at the end of the run or if baseline drift is apparent. Data reduction. Each sample peak is compared with the response of the 40/200 mgfL PA/GAL standard. After a visual inspection, a calibration curve is derived from a leastsquares analysis of the standards, and sample concentra-
tion.
Confirmation.
False-positive results for PA can result from nonphenylalanme induced fluorescence. Autoclaving and analysis of another blood spot from the original filterpaper specimen eliminates this nonspecific fluorescence (7) . Thus, for any specimen giving an apparent PA result greater than 40 mg/L on the initial analysis, a second #{188}-in. spot is autoclaved in a 12 x 75 mm polypropylene tube for 3 mm, dried for an additional 5 mm, mixed with 1.0 mL of extraction buffer, and shaken in a 40#{176}C water bath for 30 mm before analysis as above, if the PA in the autoclaved specimen is still greater than 40 mgfL, the result is considered positive for PKU screening. if the result is normal, the possibility of a punching error is investigated (see Discussion).
Specimens with GAL peaks greater than 200 mgfL are reanalyzed as follows. Punch two #{188}-in.-diameter spots into two 12 x 75 mm tubes.One sample is re-processed by the usual method to verify the initial result; for the second sample, the galactose dehydrogenase reagent is replaced by water. Any fluorescence observed in the second sample is blank related (i.e., not due to galactose). Subtract the blank value from the result of the re-analyzed sample and calculate the true concentration of galactose determined, if the result on the repeat sample, without blank correction, is less than 200 mg/L, the possibility of sample punching error is investigated (see Discussion).
Results
Precision was evaluated by repeat analysis of aqueous combined standards of PA/GAL at three concentrations: 41/99, 79/189, and 181/737 mg/L. The coefficients of variation (CVs) were 1.8/2.1, 1.5/0.74, and 1.2/1.0%, respectively (n = 40). Analysis of aqueous standards represents optimum performance of the AutoAnalyzer system. Additional variation is introduced by the nonuniformity of blood saturation on filter paper and by the extraction process. Sequential analyses of a series of20 blood-spot samples punched from the same filter paper gave CVs of (PA/GAL) 6.0/2.8, 2.3/2.6, and 3.3/3.2% formean concentrations of24/112,61/234, and 119/474 mgIL, respectively.
Carryover was measured by the low-high-low sequence of Analytical recovery was measured after addition of pure PA and GAL to hepannized whole blood, the intrinsic concentrations of which were 24 and 112 mg/L for PA and GAL, respectively. Concentrations were adjusted to the critical or cutoff value or to a clearly above-normal value. All pools were thoroughly mixed, spotted on filter paper, and allowed to dry for 24 h. One set of blood spots from each pool was punched and carried through the entire analysis, following the protocol used for the initial screening of patients' specimens. A second set of blood spots were autoclaved before analysis. The recovery data are summarized in Table   2 . For nonautoclaved specimens, the recovery of PA consistently exceeded 100%. Autoclaving reduced the recovery of PA to 102 and 93%. Autoclaved specimens cannot be analyzed for GAL.
Specificity
of the assays was checked by assaying a standard solution of 15 normallyoccurringamino acids and three sugars (glucose, fructose, and mannose). The concentrations were adjusted to approximate the upper limits of normal values expected in newborns. Analysis of this combined solution gave no measurable response over baseline.
Linearity of the standard curves for both procedures was excellent, exceeding 200 mg/L for PA and 800 mg/L for
GAL.
Performance data for PA/GAL controls, prepared from supplemented heparmnized whole-blood pools to contain 40/200 and 100/500 mg/L, show monthly CVs of8.4/7.2 for the lower-concentration pool and 6.2/5.8 for the abovenormal poo1. Each controlisassayed about 160 times per month. Besides conventional quality-control materials, we monitor performance with "blind"specimens,stateproficiency-testing specimens,and unknowns provided by the CentersforDiseaseControl, Atlanta, GA. Another parameter we use to monitor test performance is the gain setting on both fluorometers; this is observed and recorded in a manner similar to the data generated from control specimens. Any change in gain reflects a change in analyzer operating parameters. Day-to-day changes within ±5% reflect acceptable system performance.
Discussion
The dual-channel system,with combined standards and a single manifold, permits significant cost savings over use of two single-channel analyzers.A primary benefit accrues from decreased sample handling (one punch per specimen). Additional savings are realized through shared equipment (sampler and pump) and a smallerreagentrequirement.
A major objective of our study was to demonstrate a costeffective means of screening for galactosemia. The value of PKU screening is well established, based on institutional costs for nontreated cases currently exceeding $35 000 per individual per year and life expectancies exceeding 40 years.
Galactosemia occurs less frequently,1:70000, compared with approximately 1:7500 for PKU (both classical and atypical forms of PKU). Therefore, solely on the basis of a single-test program, galactose screening could not be shown to be costeffective. However, if screening for galactosemia can be viewed as an incremental(i.e., add on) costto an existing, cost-effective PKU screeningprogram, a different perspective emerges.
The costofupgrading a single-channel PA analyzer to a dual PA/GAL system, as shown in Figure 1 , requiresa galactose analytical cartridge and one additional fluorometer. This one-time charge (approximately $12 000) can be amortized over five years. (Galactose reagent costs for 100 000 analyses currently are approximately $4100 a year.) Incremental technician time, primarily for the preparation of three additional reagents, is minimal. Collecting and organizing specimens, punching,extracting, setting up the analyzer, reporting, and implementing most qualitycontrol and supervisory activities are costs not repeated by adding the second procedure. The basic increment in cost ($6500 per year) easily justifies expanding the scope of PKU screening to provide the screening procedure for galactosemia. On the basis of 100 000 specimens per year, the additional costs currently amount to $0.065 per specimen processed. This is not a rigorous cost analysis, but we provide it to place in perspective the increased costs to the program if the proposed dual-channel PA/GAL system replaces an existing single-channel PA procedure.
Another concern was to develop a system to ensure, to the greatest degree possible, a fail-safe operation. Several features are directed toward this goal. Addition of galactose to the extraction buffer produces an observable peak for each sample and facilitates identification by sequential numbering to ensure that each sample is accounted for. This results in a cutoff value corresponding to the 200 mg/L standard. The frequent use of controls (every 20th cup)ensures that the analyst reviewing the chart can easily locate groups of 20 specimens as well as identify specimens exceeding the cutoff values.
With this operating protocol we can easily recover from a mixup in specimens (transposition, misidentification of peak), the most likely error in screening programs. If the specimens are transposed in processing, and all results are negative, this is of no consequence. The presence of any presumptivepositive result, however, necessitates confirmatory analysis. if upon re-analysis the result is not positive, a misidentification of specimens is assumed. Twenty specimens on either side of the initial positive specimen are reanalyzed. If no positive is found, a spurious (false) positive is assumed.
The final consideration is the elimination of false positives. In addition to the added expense, inconvenience, and anxiety caused for the parents, a high rate of false positives CLIN. CHEM. 30/2, 290-292 (1984) will result in a loss of confidence among referral physicians. The analysis/confirmation protocol as described optimizes information available from the initial specimen and keeps false-positive reports to an absolute minimum.
